| 阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展 |
| 投稿时间：2017-11-05 修订日期：2018-01-09 点此下载全文 |
| 引用本文：龚晓斌,刘诗怡,夏天一,位华,陈万生.阿帕替尼在恶性肿瘤治疗中的临床应用与研究进展[J].药学实践杂志,2018,36(2):103~107,130 |
| 摘要点击次数: 1661 |
| 全文下载次数: 1056 |
|
| 基金项目:上海市科学技术委员会项目（13DZ1930600） |
|
| 中文摘要:抗血管生成靶向治疗是近年来肿瘤治疗的研究热点。其中，血管新生抑制剂阿帕替尼是我国自主研制的1.1类新药。临床前研究和临床试验研究表明，阿帕替尼对胃癌、肺癌、乳腺癌等多种肿瘤均具有显著的抑制活性，其安全性和有效性良好。然而，阿帕替尼的相关研究显示，目前仍存在作用机制不十分明确等问题。因此，开展进一步研究以不断提高药物的安全性、有效性和经济性，是阿帕替尼广泛应用于临床的前提。总结阿帕替尼在国内外研究现状，从作用机制、药动学过程、临床疗效、安全性和生物标志物等角度进行归纳，探讨了近年来阿帕替尼研究的热点与争议问题，实现对阿帕替尼的临床应用前景展望。 |
| 中文关键词:阿帕替尼 血管内皮细胞生长因子受体-2 靶向治疗 |
| |
| Clinical application and research progress of apatinib in cancer treatment |
|
|
| Abstract:Antiangiogenic target therapy has been a hot topic in cancer treatment recently. Apatinib is a category 1.1 new medication developed domestically. It effectively inhibits angiogenic and exhibits promising anti-tumor activity in preclinical studies. Apatinib has been successfully applied in clinical trials of multiple malignancies, such as gastric cancer, lung cancer and breast cancer with satisfactory safety and efficacy profile. However, its mechanism of action is still not fully understood. Further researches should be carried on to improve its safety, effectiveness and marketability. This review summarized the mechanism of action, pharmacokinetics, clinical efficacy, safety and biomarkers, discussed the recent progress, hot issues and clinical prospects of apatinib, |
| keywords:apatinib VEGFR2 targeted therapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
